The launch of the 750mcg teriparatide solution in Australia has seen limited availability to date. Primarily reserved for patients with severe osteoporosis who have not responded to other treatments , access is strictly managed. Present supply levels are constrained , and patients should discuss with their specialist the latest specifics on obtaini